ACRS · Company research
Aclaris Therapeutics, Inc. (ACRS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS): Stock Analysis, Technicals and Outlook - Kalkine India | Aclaris Therapeutics, Inc. (ACRS): Stock Analysis, Technicals and Outlook Kalkine India | View source ↗ | Kalkine India | Oct 9, 2026 | neutral | 0 | 0.6 |
| $ACRS stock is down 17% today. Here's what we see in our data. - Quiver Quantitative | $ACRS stock is down 17% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 1, 2026 | neutral | 0 | 0.6 |
| $ACRS stock is down 17% today. Here's what we see in our data. - Quiver Quantitative | $ACRS stock is down 17% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 1, 2026 | neutral | 0 | 0.6 |
| Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue - Simply Wall Street | Aclaris Therapeutics (ACRS) Stock Drifts Lower As Losses Deepen On Thin Revenue Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Finance | Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 1, 2026 | neutral | 0 | 0.6 |
| ACRS Forecast — Price Target — Prediction for 2027 - TradingView | ACRS Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| 3 Penny Stocks Under $5 Backed by Real Revenue Growth - MarketBeat | 3 Penny Stocks Under $5 Backed by Real Revenue Growth MarketBeat | View source ↗ | MarketBeat | Jun 20, 2026 | neutral | 0 | 0.6 |
| Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On - Yahoo Finance | Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On Yahoo Finance | View source ↗ | Yahoo Finance | Jun 7, 2026 | neutral | 0 | 0.6 |
| Aclaris Therapeutics, Inc. Stock 12‑Month Price Target Raised to $10.2, Implies 126% Upside - TradingView | Aclaris Therapeutics, Inc. Stock 12‑Month Price Target Raised to $10.2, Implies 126% Upside TradingView | View source ↗ | TradingView | May 23, 2026 | neutral | 0 | 0.6 |
| Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth - Yahoo Finance | Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth Yahoo Finance | View source ↗ | Yahoo Finance | May 4, 2026 | neutral | 0 | 0.6 |
| Aclaris Therapeutics, Inc. ($ACRS) CEO 2025 Pay Revealed - Quiver Quantitative | Aclaris Therapeutics, Inc. ($ACRS) CEO 2025 Pay Revealed Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 23, 2026 | neutral | 0 | 0.6 |
| Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights - timothysykes.com | Aclaris Therapeutics Pushes Forward with Promising Clinical Trials Amidst Financial Highlights timothysykes.com | View source ↗ | timothysykes.com | Mar 10, 2026 | neutral | 0 | 0.6 |
| There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump - Simply Wall Street | There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump Simply Wall Street | View source ↗ | Simply Wall Street | Feb 3, 2026 | neutral | 0 | 0.6 |
| Aclaris Therapeutics Inc (ACRS) Stock - Gotrade | Aclaris Therapeutics Inc (ACRS) Stock Gotrade | View source ↗ | Gotrade | Jan 13, 2026 | neutral | 0 | 0.6 |
| Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages - Slideshow (NASDAQ:ACRS) 2026-01-06 - Seeking Alpha | Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages - Slideshow (NASDAQ:ACRS) 2026-01-06 Seeking Alpha | View source ↗ | Seeking Alpha | Jan 6, 2026 | neutral | 0 | 0.6 |
| Can Aclaris Therapeutics Stock Hold Up When Markets Turn? - Trefis | Can Aclaris Therapeutics Stock Hold Up When Markets Turn? Trefis | View source ↗ | Trefis | Dec 21, 2025 | neutral | 0 | 0.6 |
| symbol__ Stock Quote Price and Forecast - CNN | symbol__ Stock Quote Price and Forecast CNN | View source ↗ | CNN | Nov 13, 2023 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.